| Literature DB >> 31436532 |
Timo Vögtle1, Sumana Sharma2, Jun Mori1, Zoltan Nagy1, Daniela Semeniak3, Cyril Scandola4, Mitchell J Geer1, Christopher W Smith1, Jordan Lane5, Scott Pollack5, Riitta Lassila6,7, Annukka Jouppila8, Alastair J Barr9, Derek J Ogg10, Tina D Howard10, Helen J McMiken10, Juli Warwicker10, Catherine Geh10, Rachel Rowlinson10, W Mark Abbott10, Anita Eckly4, Harald Schulze3, Gavin J Wright2, Alexandra Mazharian1, Klaus Fütterer11, Sundaresan Rajesh12, Michael R Douglas13,14,15, Yotis A Senis1,4.
Abstract
The immunoreceptor tyrosine-based inhibition motif (ITIM)-containing receptor G6b-B is critical for platelet production and activation. Loss of G6b-B results in severe macrothrombocytopenia, myelofibrosis and aberrant platelet function in mice and humans. Using a combination of immunohistochemistry, affinity chromatography and proteomics, we identified the extracellular matrix heparan sulfate (HS) proteoglycan perlecan as a G6b-B binding partner. Subsequent in vitro biochemical studies and a cell-based genetic screen demonstrated that the interaction is specifically mediated by the HS chains of perlecan. Biophysical analysis revealed that heparin forms a high-affinity complex with G6b-B and mediates dimerization. Using platelets from humans and genetically modified mice, we demonstrate that binding of G6b-B to HS and multivalent heparin inhibits platelet and megakaryocyte function by inducing downstream signaling via the tyrosine phosphatases Shp1 and Shp2. Our findings provide novel insights into how G6b-B is regulated and contribute to our understanding of the interaction of megakaryocytes and platelets with glycans.Entities:
Keywords: G6b-B; ITIM-receptor; biochemistry; cell biology; chemical biology; heparan sulfate; heparin; human; mouse; perlecan; platelets
Mesh:
Substances:
Year: 2019 PMID: 31436532 PMCID: PMC6742478 DOI: 10.7554/eLife.46840
Source DB: PubMed Journal: Elife ISSN: 2050-084X Impact factor: 8.140